Delivery of drugs to the brain via the blood brain barrier using colloidal carriers

Journal of Microencapsulation

Volumn 29, Issue 5, 2012, Pages 475-486

  Tucker, Ian G ^a   Yang, Lin ^a   Mujoo, Himang ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

caveolae; cerebral microvasculature; margination; nanoparticles; opsonization; receptor mediated transcytosis; targeted drug delivery; targeted nanoparticles; transcytosis

Indexed keywords

DRUG CARRIER; INTERCELLULAR ADHESION MOLECULE 1; NANOPARTICLE;

BLOOD BRAIN BARRIER; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; BRAIN; BRAIN BLOOD VESSEL; CAPILLARY; CIRCULATION; COLLOID; CYTOARCHITECTURE; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOTHELIUM CELL; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; MICROSCOPY; MICROVASCULATURE; NONHUMAN; OPSONIZATION; PARENCHYMA; PARTICLE SIZE; REVIEW; TRANSCYTOSIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84863796409     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.658445     Document Type: Review

References (110)

1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis, 2010;37:13-25.
2. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurorx, 2005;2:554-71.
3. Albanese A, Sykes EA, Chan WCW. Rough around the edges: The inflammatory response of microglial cells to spiky nanoparticles. ACS Nano, 2010;4:2490-3.
4. Alexander JS, Zivadinov R, Maghzi AH, Ganta VC, Harris MK, Minagar A. Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology, 2011;18:3-12.
5. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmaceutics, 2008;5:505-15.
6. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, et al. Pericytes regulate the blood-brain barrier. Nature, 2010;468:557-61.
7. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Delivery Rev, 2007;59:748-58.
8. Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: Diameters and densities. Acta Neuropathol, 1981;53:299-318.
9. Bertossi M, Maiorano E, Occhiogrosso M, Roncali L. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol, 1997;21:41-9.
10. Bickel U. How to measure drug transport across the blood-brain barrier. Neurorx, 2005;2:15-26.
11. Boero JA, Ascher J, Arregui A, Rovainen C, Woolsey TA. Increased brain capillaries in chronic hypoxia. J Appl Physiol, 1999;86:1211-19.
12. Brown WR, Thore CR. Review: Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol, 2011;37:56-74.
13. Caputo KE, Hammer DA. Adhesive dynamics simulation of G-proteinmediated chemokine-activated neutrophil adhesion. Biophys J, 2009;96:2989-3004.
14. Caputo KE, Lee D, King MR, Hammer DA. Adhesive dynamics simulations of the shear threshold effect for leukocytes. Biophys J, 2007;92:787-97.
15. Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci, 2011;31:13272-80.
16. Carman CV, Sage PT, Sciuto TE, De La Fuente MA, Geha RS, Ochs HD, Dvorak HF, Dvorak AM, Springer TA. Transcellular diapedesis is initiated by invasive podosomes. Immunity, 2007;26:784-97.
17. Carmignoto G, Gomez-Gonzalo M. The contribution of astrocyte signalling to neurovascular coupling. Brain Res Rev, 2010;63:138-48.
18. Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, Pu PY, Betbeder D. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm, 2009;379:285-92.
19. Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology, 2007;364:55-63.
20. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun, 2009;77:120-7.
21. Chen H, Tang L, Qin Y, Yin Y, Tang J, Tang W, Sun X, Zhang Z, Liu J, He Q. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci, 2010;40:94-102.
22. Cho EC, Zhang Q, Xia Y. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat Nanotechnol, 2011;6:385-91.
23. Cooper I, Malina KCK, Cagnotto A, Bazzoni G, Salmona M, Teichberg VI. Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: Coordinated cell killing and remodeling of intercellular junctions. J Neurochem, 2011;116:467-75.
24. Debbage P, Thurner GC. Nanomedicine faces barriers. Pharmaceuticals, 2010;3:3371-416.
25. Demeule M, Currie JC, Bertrand Y, Ché C, Nguyen T, Régina A, Gabathuler R, Castaigne JP, Béliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem, 2008;106:1534-44.
26. Dhuria SV, Hanson LR, Frey WHI. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci, 2010;99:1654-73.
27. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes cross the blood-brain barrier: A potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci, 2006;26:1098-106.
28. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-î-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur J Pharm Sci, 2006;27:27-36.
29. Fernandez-Klett F, Offenhauser N, Dirnagl U, Priller J, Lindauer U. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci USA, 2010;107:22290-5.
30. Freund JB, Orescanin MM. Cellular flow in a small blood vessel. J Fluid Mech, 2011;671:466-90.
31. Gabathuler R. Approaches to transport therapeutic drugs across the bloodbrain barrier to treat brain diseases. Neurobiol Dis, 2010;37:48-57.
32. Gao H, Shi W, Freund LB. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci USA, 2005;102:9469-74.
33. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol, 2007;2:249-55.
34. Georgieva JV, Kalicharan D, Couraud PO, Romero IA, Weksler B, Hoekstra D, Zuhorn IS. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol Ther, 2011;19:318-25.
35. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin Invest, 1997;99:14-18.
36. Grab DJ, Garcia-Garcia JC, Nikolskaia OV, Kim YV, Brown A, Pardo CA, Zhang Y, Becker KG, Wilson BA, de A Lima AP, et al. Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis, 2009;3:e479.
37. Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, Keski-Rahkonen P, Venäläinen T, Hokkanen J, Mönkkönen J, Suhonen M, Forsberg MM. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm, 2010;402:27-36.
38. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J, 2008;10:455-72.
39. Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem, 2005;280:17057-61.
40. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci, 2009;66:2873-96.
41. Huang RB, Mocherla S, Heslinga MJ, Charoenphol P, Eniola-Adefeso O. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review). Mol Membr Biol, 2010b;27:190-205.
42. Huang L, Sullenger B, Juliano R. The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. J Drug Target, 2010a;18:567-74.
43. Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: In vitro characterisation. J Microencapsulation, 2011;28:21-8.
44. Jain SK, Paul-Satyaseela M, Lamichhane G, Kim KS, Bishai WR. Mycobacterium tuberculosis invasion and traversal across an in vitro human blood-brain barrier as a pathogenic mechanism for central nervous system tuberculosis. J Infect Dis, 2006;193:1287-95.
45. Jeynes B, Provias J. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res, 2011;89:22-8.
46. Jogani V, Jinturkar K, Vyas TK, Misra A. Recent patents review on intranasal administration for CNS drug delivery. Recent patents on drug delivery and formulation, 2008;2:25-40.
47. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res, 2007;24:1759-71.
48. Jones AT. Gateways and tools for drug delivery: Endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm, 2008;354:34-8.
49. Jong A, Wu CH, Prasadarao NV, Kwon-Chung KJ, Chang YC, Ouyang Y, Shackleford GM, Huang SH. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-a activation. Cell Microbiol, 2008a;10:1854-65.
50. Jong A, Wu CH, Shackleford GM, Kwon-Chung KJ, Chang YC, Chen HM, Ouyang Y, Huang SH. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol, 2008b;10:1313-26.
51. Kaminskas LM, McLeod VM, Porter HCJ, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci, 2011;100(11):5069-77.
52. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One, 2009;4:e4627.
53. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: Implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv, 2011;8:343-57.
54. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials, 2009;30:6976-85.
55. Kim S, Kong RL, Popel AS, Intaglietta M, Johnson PC. Temporal and spatial variations of cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol, 2007;293:H1526-35.
56. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 2002;10:317-25.
57. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature, 2010;465:478-82.
58. LaManna JC, Chavez JC, Pichiule P. Structural and functional adaptation to hypoxia in the rat brain. J Exp Biol, 2004;207:3163-9.
59. Lee SY, Ferrari M, Decuzzi P. Design of bio-mimetic particles with enhanced vascular interaction. J Biomech, 2009;42:1885-90.
60. Ligade PC, Jadhav KR, Kadam VJ. Brain drug delivery system: An overview. Curr Drug Ther, 2010;5:105-10.
61. Lokkegaard A, Nyengaard JR, West MJ. Stereological estimates of number and length of capillaries in subdivisions of the human hippocampal region. Hippocampus, 2001;11:726-40.
62. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol, 2004;19:535-64.
63. Maruvada R, Kim KS. Extracellular loops of the Escherichia coli outer membrane protein A contribute to the pathogenesis of meningitis. J Infect Dis, 2010;203:131-40.
64. Meier-Ruge W, Hunziker O, Schulz U. Stereological changes in the capillary network and nerve cells of the aging human brain. Mech Ageing Dev, 1980;14:233-43.
65. Mendu DR, Katinger H, Sodroski J, Kim KS. HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. Biochem Biophys Res Commun, 2007;363:466-71.
66. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci, 2010;31:246-54.
67. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target, 2006;14:45-53.
68. Nakaoke R, Ryerse JS, Niwa M, Banks WA. Human immunodeficiency virus type 1 transport across the in vitro mouse brain endothelial cell monolayer. Exp Neurol, 2005;193:101-9.
69. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the bloodcerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev, 2010;23:858-83.
70. Nguyen L, Pieters J. The Trojan horse: Survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol, 2005;15:269-76.
71. Nikolskaia OV, Kim YV, Kovbasnjuk O, Kim KJ, Grab DJ. Entry of Trypanosoma brucei gambiense into microvascular endothelial cells of the human blood-brain barrier. Int J Parasitol, 2006;36:513-9.
72. Oh P, Borgstrom P, Witkiewicz H, Li Y, Borgström BJ, Chrastina A, Iwata K, Zinn KR, Baldwin R, Testa JE, et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol, 2007;25:327-37.
73. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2005;2:3-14.
74. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol, 2001;3:473-83.
75. Peppiatt CM, Howarth C, Mobbs P, Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature, 2006;443:700-4.
76. Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of amyloid- across the blood-brain barrier. Neurobiol Aging, 2011;32:2323.e111.
77. Potschka H. Targeting the brain-surmounting or bypassing the bloodbrain barrier. Handb Exp Pharmacol, 2010;197:411-31.
78. Predescu SA, Predescu DN, Malik AB. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am J Physiol Lung Cell Mol Physiol, 2007;293:L823-42.
79. Ragnaill MN, Brown M, Ye D, Bramini M, Callanan S, Lynch I, Dawson KA. Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur J Pharm Biopharm, 2011;77:360-7.
80. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J, 2004;377:159-69.
81. Ring A, Weiser JN, Tuomanen EI. Pneumococcal trafficking across the blood-brain barrier molecular analysis of a novel bidirectional pathway. J Clin Invest, 1998;102:347-60.
82. Rippe B, Rosengren BI, Carlsson O, Venturoli D. Transendothelial transport: The vesicle controversy. J Vasc Res, 2002;39:375-90.
83. Sakhalkar HS, Dalal MK, Salem AK, Ansari R, Fu J, Kiani MF, Kurjiaka DT, Hanes J, Shakesheff KM, Goetz DJ. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci USA, 2003;100:15895-900.
84. Shin JS, Abraham SN. Caveolae as portals of entry for microbes. Microbes Infect, 2001;3:755-61.
85. Simone E, Ding BS, Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res, 2009;335:283-300.
86. Simpson JE, Wharton SB, Cooper J, Gelsthorpe C, Baxter L, Forster G, Shaw PJ, Savva G, Matthews FE, Brayne C, et al. Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain. Neurosci Lett, 2010;486:246-51.
87. Spector R, Johanson CE. Vectorial ligand transport through mammalian choroid plexus. Pharm Res, 2010;27:2054-62.
88. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: How to ''open'' the blood brain barrier. Curr Neuropharm, 2008;6:179-92.
89. Stewart PA. Endothelial vesicles in the blood-brain barrier: Are Teng CH, Cai M, Shin S, Xie Y, Kim KJ, Khan NA, Di Cello F, Kim KS. Escherichia coli K1 RS218 interacts with human brain microvascular endothelial cells via type 1 fimbria bacteria in the fimbriated state. Infect Immun, 2005;73:2923-31.
90. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res, 2009;26:2486-94.
91. Thorne RG, Lakkaraju A, Rodriguez-Boulan E, Nicholson C. In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc Natl Acad Sci USA, 2008;105:8416-21.
92. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci USA, 2006;103:5567-72.
93. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem, 1990;54:1882-8.
94. Tucker IG. Drug delivery to the brain via the blood-brain barrier: A review of the literature and some recent patent disclosures. Ther Deliv, 2011;2:311-27.
95. Unekawa M, Tomita M, Tomita Y, Toriumi H, Miyaki K, Suzuki N. RBC velocities in single capillaries of mouse and rat brains are the same, despite 10-fold difference in body size. Brain Res, 2010; 1320:69-73.
96. Van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharm Res, 2011;28:456-71.
97. Vercauteren D, Vandenbroucke RE, Jones AT, Rejman J, Demeester J, De Smedt SC, Sanders NN, Braeckmans K. The use of inhibitors to study endocytic pathways of gene carriers: Optimization and pitfalls. Mol Ther, 2010;18:561-9.
98. Visser CC, Stevanovic S, Voorwinden LH, Gaillard PJ, Crommelin DJ, Danhof M, De Boer AG. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target, 2004;12:145-50.
99. Von Wedel-Parlow M, Schrot S, Lemmen J, Treeratanapiboon L, Wegener J, Galla HJ. Neutrophils cross the BBB primarily on transcellular pathways: An in vitro study. Brain Res, 2011;1367:62-76.
100. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell ''sees'' in bionanoscience. J Am Chem Soc, 2010;132:5761-8.
101. Wang BY, Xia AX, Chen PP, Ni L, Liu FH, Li FZ. Blood-brain barrier transport of drug-loaded nanoparticle: Research advances. J Int Pharm Res, 2010;37:40-2.
102. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, et al. Bloodbrain barrier-specific properties of a human adult brain endothelial cell line. FASEB J, 2005;19:1872-4.
103. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the bloodbrain barrier. J Controlled Release, 2011;154:103-7.
104. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: Challenges, solutions and future prospects. Curr Pharm Des, 2010;16:2298-307.
105. Zaki NM, Tirelli N. Gateways for the intracellular access of nanocarriers: A review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin Drug Deliv, 2010;7:895-913.
106. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: Geriatric relevance of a critical brain-body interface. J Am Geriatr Soc, 2010;58:1749-57.
107. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, Kreuter J. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target, 010;18:842-8.
108. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Release, 2009;137:78-86.
109. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of nanoparticles. Adv Mater (Weinheim Ger), 2009;21:419-24.
110. Zhou QH, Boado RJ, Lu JZ, Hui EKW, Pardridge WM. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol Pharmaceutics, 2010;7:2148-55.